Alliance Pharma PLC Update on Interim Dividend Timetable (8493R)
10 November 2021 - 03:36AM
UK Regulatory
TIDMAPH
RNS Number : 8493R
Alliance Pharma PLC
09 November 2021
For immediate release 9 November 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Update on interim dividend timetable
In the Group's interim results for the six months ended 30 June
2021 announced on 21 September 2021, Alliance stated that its 2021
interim dividend payment of 0.563p per share (the "Interim
Dividend") would be paid on 7 January 2022 to shareholders on the
register on 24 December 2021.
Alliance would now like to update the market that it has brought
forward the record date for the Interim Dividend to 17 December
2021, with the payment date remaining as 7 January 2022 as
previously announced.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Duncan Monteith
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group. Our purpose is to improve the lives of consumers and
patients through making available a range of clinically valuable
healthcare products.
Our core focus is on the marketing of Consumer Healthcare
brands, complemented by a smaller Prescription Medicines business.
In total, we hold marketing rights to around 80 brands, with
revenues generated from a mix of direct, distributor and e-commerce
sales.
Headquartered in the UK, the Group employs around 250 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics
operations, we remain asset-light and focused on maximising the
value of our brands.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DIVBLBDBSXGDGBC
(END) Dow Jones Newswires
November 09, 2021 11:36 ET (16:36 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024